Jan’s PhD was in genetic toxicology but she has spent a large part of her career in the Life Science industry, as both an R&D scientist and in global product management, providing tools and reagents to pharma in high throughput screening and safety assessment functions. Latterly, Jan has worked in the cell therapy area, providing equipment and support for production of these new therapies. She has worked extensively with iPSCs for cardiotoxicology and neuro degenerative diseases and participated in the FDA CiPA initiative from 2013. As Prinicpal, Medicines at Humane World for Animals, Jan has initiated the medicines workstream to change the way medicines are tested from animal based methods to new approach methodologies (NAMs), globally and with harmonization across regions.